Imaging the glutamate system in humans: Relevance to drug discovery for schizophrenia

Current Pharmaceutical Design

Volumn 15, Issue 22, 2009, Pages 2594-2602

  Stone, James M ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

fMRI; Glutamate; Glutamine; Ketamine; MRS; NMDA; PET; Schizophrenia; SPECT

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; ACETYLCYSTEINE; BRAIN DERIVED NEUROTROPHIC FACTOR; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; CNS 1261; CREATINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; FLUMAZENIL C 11; FLUORINE 18; GLUTAMATE DECARBOXYLASE 67; GLUTAMATE RECEPTOR; GLUTAMATE RECEPTOR AGONIST; GLUTAMIC ACID; GLUTAMINE; GLUTATHIONE; GLYCINEB AGONIST; KETAMINE; LAMOTRIGINE; METABOTROPIC RECEPTOR 5; MUSCARINIC M1 RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; RACLOPRIDE; TRACER; UNCLASSIFIED DRUG;

BINDING AFFINITY; BRAIN BLOOD FLOW; BRAIN FUNCTION; BRAIN METABOLISM; CINGULATE GYRUS; DOPAMINE RELEASE; DOPAMINERGIC TRANSMISSION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG TARGETING; FRONTAL CORTEX; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GABAERGIC TRANSMISSION; GENE EXPRESSION; GLUTAMATERGIC TRANSMISSION; HUMAN; LIMBIC SYSTEM; MEMORY CONSOLIDATION; NEUROIMAGING; NEUROTRANSMISSION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; RECEPTOR BINDING; RECEPTOR BLOCKING; REVIEW; SCHIZOPHRENIA; STIMULUS RESPONSE; VISUAL CORTEX; WORKING MEMORY;

BRAIN; DRUG DELIVERY SYSTEMS; DRUG DISCOVERY; GLUTAMIC ACID; HUMANS; KETAMINE; MAGNETIC RESONANCE SPECTROSCOPY; MODELS, NEUROLOGICAL; RECEPTORS, N-METHYL-D-ASPARTATE; SCHIZOPHRENIA; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 69249108159     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161209788957438     Document Type: Review

References (90)

1. Kapur S. Psychosis as a state of aberrant salience: A framework linking biology, phenomenology, and pharmacology in schizophrenia. Am J Psychiatry 2003; 160: 13-23.
2. Kapur S, Mamo D. Half a century of antipsychotics and still a central role for dopamine D2 receptors. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27: 1081-90.
3. Shenton ME, Dickey CC, Frumin M, McCarley RW. A review of MRI findings in schizophrenia. Schizophr Res 2001; 49: 1-52.
4. Pantelis C, Velakoulis D, McGorry PD, Wood SJ, Suckling J, Phillips LJ, et al. Neuroanatomical abnormalities before and after onset of psychosis: A cross-sectional and longitudinal MRI comparison. Lancet 2003; 361: 281-8.
5. Cahn W, van Haren NE, Hulshoff Pol HE, Schnack HG, Caspers E, Laponder DA, et al. Brain volume changes in the first year of illness and 5-year outcome of schizophrenia. Br J Psychiatry 2006; 189: 381-2.
6. Stone JM, Morrison PD, Pilowsky LS. Glutamate and dopamine dysregulation in schizophrenia--a synthesis and selective review. J Psychopharmacol 2007; 21: 440-52.
7. Carlsson M, Carlsson A. Interactions between glutamatergic and monoaminergic systems within the basal ganglia--implications for schizophrenia and Parkinson's disease. Trends Neurosci 1990; 13: 272-6.
8. Lisman JE, Coyle JT, Green RW, Javitt DC, Benes FM, Heckers S, et al. Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia. Trends Neurosci 2008; 31: 234-42.
9. Goff DC, Coyle JT. The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am J Psychiatry 2001; 158: 1367-77.
10. Laruelle M, Kegeles LS, Abi-Dargham A. Glutamate, dopamine, and schizophrenia: From pathophysiology to treatment. Ann N Y Acad Sci 2003; 1003: 138-58.
11. Stone JM. Glutamatergic dysfunction in schizophrenia. Adv Schizophr Clin Psychiatry 2007; 3: 34-39.
12. Krystal JH, Perry EB, Jr., Gueorguieva R, Belger A, Madonick SH, Abi-Dargham A, et al. Comparative and interactive human psychopharmacologic effects of ketamine and amphetamine: Implications for glutamatergic and dopaminergic model psychoses and cognitive function. Arch Gen Psychiatry 2005; 62: 985-94.
13. Vollenweider FX, Geyer MA. A systems model of altered consciousness: integrating natural and drug-induced psychoses. Brain Res Bull 2001; 56: 495-507.
14. Olney JW, Farber NB. Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry 1995; 52: 998-1007.
15. Moghaddam B, Adams B, Verma A, Daly D. Activation of glutamatergic neurotransmission by ketamine: A novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci 1997; 17: 2921-7.
16. Lorrain DS, Baccei CS, Bristow LJ, Anderson JJ, Varney MA. Effects of ketamine and N-methyl-D-aspartate on glutamate and dopamine release in the rat prefrontal cortex: Modulation by a group II selective metabotropic glutamate receptor agonist LY379268. Neuroscience 2003; 117: 697-706.
17. Sharp FR, Tomitaka M, Bernaudin M, Tomitaka S. Psychosis: Pathological activation of limbic thalamocortical circuits by psychomimetics and schizophrenia? Trends Neurosci 2001; 24: 330-4.
18. Deutsch SI, Rosse RB, Schwartz BL, Mastropaolo J. A revised excitotoxic hypothesis of schizophrenia: Therapeutic implications. Clin Neuropharmacol 2001; 24: 43-9.
19. Olney JW, Newcomer JW, Farber NB. NMDA receptor hypofunction model of schizophrenia. J Psychiatr Res 1999; 33: 523-33.
20. Benes FM. Emerging principles of altered neural circuitry in schizophrenia. Brain Res Brain Res Rev 2000; 31: 251-69.
21. Reynolds GP, Abdul-Monim Z, Neill JC, Zhang ZJ. Calcium binding protein markers of GABA deficits in schizophrenia--postmortem studies and animal models. Neurotox Res 2004; 6: 57-61.
22. Lewis DA, Hashimoto T, Volk DW. Cortical inhibitory neurons and schizophrenia. Nat Rev Neurosci 2005; 6: 312-24.
23. Harrison PJ, Weinberger DR. Schizophrenia genes, gene expression, and neuropathology: On the matter of their convergence. Mol Psychiatry 2005; 10: 40-68.
24. Kapur S, Seeman P. NMDA receptor antagonists ketamine and PCP have direct effects on the dopamine D(2) and serotonin 5-HT(2) receptors-implications for models of schizophrenia. Mol Psychiatry 2002; 7: 837-44.
25. Pomarol-Clotet E, Honey GD, Murray GK, Corlett PR, Absalom AR, Lee M, et al. Psychological effects of ketamine in healthy volunteers. Phenomenological study. Br J Psychiatry 2006; 189: 173-9.
26. Stone JM, Pilowsky LS. Psychopathological consequences of ketamine. Br J Psychiatry 2006; 189: 565-6.
27. Lahti AC, Holcomb HH, Medoff DR, Tamminga CA. Ketamine activates psychosis and alters limbic blood flow in schizophrenia. Neuroreport 1995; 6: 869-72.
28. Holcomb HH, Lahti AC, Medoff DR, Weiler M, Tamminga CA. Sequential regional cerebral blood flow brain scans using PET with H2(15)O demonstrate ketamine actions in CNS dynamically. Neuropsychopharmacology 2001; 25: 165-72.
29. Langsjo JW, Kaisti KK, Aalto S, Hinkka S, Aantaa R, Oikonen V, et al. Effects of subanesthetic doses of ketamine on regional cerebral blood flow, oxygen consumption, and blood volume in humans. Anesthesiology 2003; 99: 614-23.
30. Vollenweider FX, Leenders KL, Scharfetter C, Antonini A, Maguire P, Missimer J, et al. Metabolic hyperfrontality and psychopathology in the ketamine model of psychosis using positron emission tomography (PET) and [18]Ffluorodeoxyglucose (FDG). Eur Neuropsychopharmacol 1997; 7: 9-24.
31. Vollenweider FX, Leenders KL, Oye I, Hell D, Angst J. Differential psychopathology and patterns of cerebral glucose utilisation produced by (S)- and (R)-ketamine in healthy volunteers using positron emission tomography (PET). Eur Neuropsychopharmacol 1997; 7: 25-38.
32. Abel KM, Allin MP, Kucharska-Pietura K, Andrew C, Williams S, David AS, et al. Ketamine and fMRI BOLD signal: Distinguishing between effects mediated by change in blood flow versus change in cognitive state. Hum Brain Mapp 2003; 18: 135-45.
33. Abel KM, Allin MP, Kucharska-Pietura K, David A, Andrew C, Williams S, et al. Ketamine alters neural processing of facial emotion recognition in healthy men: An fMRI study. Neuroreport 2003; 14: 387-91.
34. Honey RA, Honey GD, O'Loughlin C, Sharar SR, Kumaran D, Bullmore ET, et al. Acute ketamine administration alters the brain responses to executive demands in a verbal working memory task: An FMRI study. Neuropsychopharmacology 2004; 29: 1203-14.
35. Honey GD, Honey RA, O'Loughlin C, Sharar SR, Kumaran D, Suckling J, et al. Ketamine disrupts frontal and hippocampal contribution to encoding and retrieval of episodic memory: An fMRI study. Cereb Cortex 2005; 15: 749-59.
36. Northoff G, Richter A, Bermpohl F, Grimm S, Martin E, Marcar VL, et al. NMDA hypofunction in the posterior cingulate as a model for schizophrenia: An exploratory ketamine administration study in fMRI. Schizophr Res 2005; 72: 235-48.
37. Smith GS, Schloesser R, Brodie JD, Dewey SL, Logan J, Vitkun SA, et al. Glutamate modulation of dopamine measured in vivo with positron emission tomography (PET) and 11C-raclopride in normal human subjects. Neuropsychopharmacology 1998; 18: 18-25.
38. Vollenweider FX, Vontobel P, Oye I, Hell D, Leenders KL. Effects of (S)-ketamine on striatal dopamine: A 11Craclopride PET study of a model psychosis in humans. J Psychiatr Res 2000; 34: 35-43
39. Aalto S, Hirvonen J, Kajander J, Scheinin H, Nagren K, Vilkman H, et al. Ketamine does not decrease striatal dopamine D2 receptor binding in man. Psychopharmacology (Berl) 2002; 164: 401-6.
40. Kegeles LS, Martinez D, Kochan LD, Hwang DR, Huang Y, Mawlawi O, et al. NMDA antagonist effects on striatal dopamine release: Positron emission tomography studies in humans. Synapse 2002; 43: 19-29.
41. Kegeles LS, Abi-Dargham A, Zea-Ponce Y, Rodenhiser-Hill J, Mann JJ, Van Heertum RL, et al. Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: Implications for schizophrenia. Biol Psychiatry 2000; 48: 627-40
42. Aalto S, Ihalainen J, Hirvonen J, Kajander J, Scheinin H, Tanila H, et al. Cortical glutamate-dopamine interaction and ketamine-induced psychotic symptoms in man. Psychopharmacology (Berl) 2005; 182: 375-83.
43. Narendran R, Frankle WG, Keefe R, Gil R, Martinez D, Slifstein M, et al. Altered prefrontal dopaminergic function in chronic recreational ketamine users. Am J Psychiatry 2005; 162: 2352-9.
44. Abi-Dargham A, Moore H. Prefrontal DA transmission at D1 receptors and the pathology of schizophrenia. Neuroscientist 2003; 9: 404-16.
45. Matusch A, Hurlemann R, Rota Kops E, Winz OH, Elmenhorst D, Herzog H, et al. Acute S-ketamine application does not alter cerebral [18]Faltanserin binding: A pilot PET study in humans. J Neural Transm 2007; 114: 1433-42.
46. Heinzel A, Steinke R, Poeppel TD, Grosser O, Bogerts B, Otto H, et al. S-ketamine and GABA-A-receptor interaction in humans: An exploratory study with I-123-iomazenil SPECT. Hum Psychopharmacol 2008; 23: 549-54.
47. Salmi E, Langsjo JW, Aalto S, Nagren K, Metsahonkala L, Kaisti KK, et al. Subanesthetic ketamine does not affect 11C-flumazenil binding in humans. Anesth Analg 2005; 101: 722-5, table of contents.
48. Rothman DL, Behar KL, Hyder F, Shulman RG. In vivo NMR studies of the glutamate neurotransmitter flux and neuroenergetics: Implications for brain function. Annu Rev Physiol 2003; 65: 401-27.
49. Rowland LM, Bustillo JR, Mullins PG, Jung RE, Lenroot R, Landgraf E, et al. Effects of ketamine on anterior cingulate glutamate metabolism in healthy humans: A 4-T proton MRS study. Am J Psychiatry 2005; 162: 394-6.
50. Erlandsson K, Bressan RA, Mulligan RS, Gunn RN, Cunningham VJ, Owens J, et al. Kinetic modelling of [123I]CNS 1261--a potential SPET tracer for the NMDA receptor. Nucl Med Biol 2003; 30: 441-54.
51. Waterhouse RN. Imaging the PCP site of the NMDA ion channel. Nucl Med Biol 2003; 30: 869-78.
52. Stone JM, Erlandsson K, Arstad E, Bressan RA, Squassante L, Teneggi V, et al. Ketamine displaces the novel NMDA receptor SPET probe [(123)I]CNS-1261 in humans in vivo. Nucl Med Biol 2006; 33: 239-43.
53. Stone JM, Erlandsson K, Arstad E, Squassante L, Teneggi V, Bressan RA, et al. Relationship between ketamine-induced psychotic symptoms and NMDA receptor occupancy: A [(123)I]CNS-1261 SPET study. Psychopharmacology (Berl) 2008; 197: 401-8.
54. Bartha R, Williamson PC, Drost DJ, Malla A, Carr TJ, Cortese L, et al. Measurement of glutamate and glutamine in the medial prefrontal cortex of never-treated schizophrenic patients and healthy controls by proton magnetic resonance spectroscopy. Arch Gen Psychiatry 1997; 54: 959-65.
55. Theberge J, Bartha R, Drost DJ, Menon RS, Malla A, Takhar J, et al. Glutamate and glutamine measured with 4.0 T proton MRS in never-treated patients with schizophrenia and healthy volunteers. Am J Psychiatry 2002; 159: 1944-6.
56. Tibbo P, Hanstock C, Valiakalayil A, Allen P. 3-T proton MRS investigation of glutamate and glutamine in adolescents at high genetic risk for schizophrenia. Am J Psychiatry 2004; 161: 1116-8.
57. Davies MA, Compton-Toth BA, Hufeisen SJ, Meltzer HY, Roth BL. The highly efficacious actions of N-desmethylclozapine at muscarinic receptors are unique and not a common property of either typical or atypical antipsychotic drugs: Is M1 agonism a prerequisite for mimicking clozapine's actions? Psychopharmacology (Berl) 2005; 178: 451-60.
58. Theberge J, Al-Semaan Y, Drost DJ, Malla AK, Neufeld RW, Bartha R, et al. Duration of untreated psychosis vs. N-acetylaspartate and choline in first episode schizophrenia: A 1H magnetic resonance spectroscopy study at 4.0 Tesla. Psychiatry Res 2004; 131: 107-14.
59. Theberge J, Williamson KE, Aoyama N, Drost DJ, Manchanda R, Malla AK, et al. Longitudinal grey-matter and glutamatergic losses in first-episode schizophrenia. Br J Psychiatry 2007; 191: 325-34.
60. Ohrmann P, Siegmund A, Suslow T, Spitzberg K, Kersting A, Arolt V, et al. Evidence for glutamatergic neuronal dysfunction in the prefrontal cortex in chronic but not in first-episode patients with schizophrenia: a proton magnetic resonance spectroscopy study. Schizophr Res 2005; 73: 153-7.
61. Choe BY, Kim KT, Suh TS, Lee C, Paik IH, Bahk YW, et al. 1H magnetic resonance spectroscopy characterization of neuronal dysfunction in drug-naive, chronic schizophrenia. Acad Radiol 1994; 1: 211-6.
62. Choe BY, Suh TS, Shinn KS, Lee CW, Lee C, Paik IH. Observation of metabolic changes in chronic schizophrenia after neuroleptic treatment by in vivo hydrogen magnetic resonance spectroscopy. Invest Radiol 1996; 31: 345-52.
63. Stanley JA, Williamson PC, Drost DJ, Rylett RJ, Carr TJ, Malla A, et al. An in vivo proton magnetic resonance spectroscopy study of schizophrenia patients. Schizophr Bull 1996; 22: 597-609.
64. Szulc A, Galinska B, Tarasow E, Dzienis W, Kubas B, Konarzewska B, et al. The effect of risperidone on metabolite measures in the frontal lobe, temporal lobe, and thalamus in schizophrenic patients. A proton magnetic resonance spectroscopy (1H MRS). Pharmacopsychiatry 2005; 38: 214-9.
65. Goff DC, Hennen J, Lyoo IK, Tsai G, Wald LL, Evins AE, et al. Modulation of brain and serum glutamatergic concentrations following a switch from conventional neuroleptics to olanzapine. Biol Psychiatry 2002; 51: 493-7.
66. Do KQ, Trabesinger AH, Kirsten-Kruger M, Lauer CJ, Dydak U, Hell D, et al. Schizophrenia: Glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo. Eur J Neurosci 2000; 12: 3721-.
67. Matsuzawa D, Obata T, Shirayama Y, Nonaka H, Kanazawa Y, Yoshitome E, et al. Negative correlation between brain glutathione level and negative symptoms in schizophrenia: A 3T 1H-MRS study. PLoS ONE 2008; 3: e1944.
68. Bressan RA, Erlandsson K, Stone JM, Mulligan RS, Krystal JH, Ell PJ, et al. Impact of schizophrenia and chronic antipsychotic treatment on [123I]CNS-1261 binding to N-methyl-D-aspartate receptors in vivo. Biol Psychiatry 2005; 58: 41-6.
69. Pilowsky LS, Bressan RA, Stone JM, Erlandsson K, Mulligan RS, Krystal JH, et al. First in vivo evidence of an NMDA receptor deficit in medication-free schizophrenic patients. Mol Psychiatry 2006; 11: 118-9.
70. Eyles DW, McGrath JJ, Reynolds GP. Neuronal calcium-binding proteins and schizophrenia. Schizophr Res 2002; 57: 27-34.
71. Lechner SM. Glutamate-based therapeutic approaches: Inhibitors of glycine transport. Curr Opin Pharmacol 2006; 6: 75-81.
72. Stone JM, Pilowsky LS. Novel targets for drugs in schizophrenia. CNS Neurol Disord Drug Targets 2007; 6: 265-72.
73. Moghaddam B. Targeting metabotropic glutamate receptors for treatment of the cognitive symptoms of schizophrenia. Psychopharmacology (Berl) 2004; 174: 39-44.
74. Pisani A, Gubellini P, Bonsi P, Conquet F, Picconi B, Centonze D, et al. Metabotropic glutamate receptor 5 mediates the potentiation of N-methyl-D-aspartate responses in medium spiny striatal neurons. Neuroscience 2001; 106: 579-87.
75. Javitt DC. Glutamate as a therapeutic target in psychiatric disorders. Mol Psychiatry 2004; 9: 984-97, 979.
76. Raedler TJ, Knable MB, Jones DW, Urbina RA, Gorey JG, Lee KS, et al. In vivo determination of muscarinic acetylcholine receptor availability in schizophrenia. Am J Psychiatry 2003; 160: 118-27.
77. Shekhar A, Potter WZ, Lightfoot J, Lienemann J, Dube S, Mallinckrodt C, et al. Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia. Am J Psychiatry 2008; 165: 1033-9.
78. Freedman R, Olincy A, Buchanan RW, Harris JG, Gold JM, Johnson L, et al. Initial phase 2 trial of a nicotinic agonist in schizophrenia. Am J Psychiatry 2008; 165: 1040-7.
79. Takahashi M, Shirakawa O, Toyooka K, Kitamura N, Hashimoto T, Maeda K, et al. Abnormal expression of brain-derived neurotrophic factor and its receptor in the corticolimbic system of schizophrenic patients. Mol Psychiatry 2000; 5: 293-300.
80. Angelucci F, Mathe AA, Aloe L. Brain-derived neurotrophic factor and tyrosine kinase receptor TrkB in rat brain are significantly altered after haloperidol and risperidone administration. J Neurosci Res 2000; 60: 783-94.
81. Hosak L, Libiger J. Antiepileptic drugs in schizophrenia: A review. Eur Psychiatry 2002; 17: 371-8.
82. Guidotti A, Auta J, Davis JM, Dong E, Grayson DR, Veldic M, et al. GABAergic dysfunction in schizophrenia: New treatment strategies on the horizon. Psychopharmacology (Berl) 2005; 180: 191-205.
83. Patil ST, Zhang L, Martenyi F, Lowe SL, Jackson KA, Andreev BV, et al. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: A randomized Phase 2 clinical trial. Nat Med 2007; 13: 1102-7.
84. Reynolds GP, Harte MK. The neuronal pathology of schizophrenia: molecules and mechanisms. Biochem Soc Trans 2007; 35: 433-6.
85. Danos P, Baumann B, Bernstein HG, Franz M, Stauch R, Northoff G, et al. Schizophrenia and anteroventral thalamic nucleus: Selective decrease of parvalbumin-immunoreactive thalamocortical projection neurons. Psychiatry Res 1998; 82: 1-10.
86. Theberge J, Al-Semaan Y, Williamson PC, Menon RS, Neufeld RW, Rajakumar N, et al. Glutamate and glutamine in the anterior cingulate and thalamus of medicated patients with chronic schizophrenia and healthy comparison subjects measured with 4.0-T proton MRS. Am J Psychiatry 2003; 160: 2231-3.
87. Abbott C, Bustillo J. What have we learned from proton magnetic resonance spectroscopy about schizophrenia? A critical update. Curr Opin Psychiatry 2006; 19: 135-9.
88. Eser D, Baghai TC, Schule C, Nothdurfter C, Rupprecht R. Neuroactive steroids as endogenous modulators of anxiety. Curr Pharm Des 2008; 14(33): 3525-33.
89. Malorni W, Farrace MG, Rodolfo C, Piacentini M. Type 2 transglutaminase in neurodegenerative diseases: The mitochondrial connection. Curr Pharm Des 2008; 14(3): 278-88.
90. ten Hove M, Neubauer S. The application of NMR spectroscopy for the study of heart failure. Curr Pharm Des 2008; 14(18): 1787-97.